ScholarLens Back to search
2017•Kidney International ReportsOpen access

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway

Joseph Wang, Beth A. Vogt, Sidharth Kumar Sethi, Matthew Gordon Sampson, Virginia Vega-Warner, Edgar A. Otto, Rupesh Raina

Open full text 0 citations

Abstract

Phosphate homeostasis is a complex process involving communication among bones, kidneys, and other organ systems.1,2 This is tightly regulated through parathyroid hormone (PTH) and bone-derived fibroblast growth factor 23 (FGF23).1–3 Disruption of either pathway has been associated with a number of disorders resulting in hypo- or hyperphosphatemia.1 These disorders tend to have profound effects on the human body through demineralization or ectopic calcifications/stone production.1

About this research paper

What this paper is about

Phosphate homeostasis is a complex process involving communication among bones, kidneys, and other organ systems.1,2 This is tightly regulated through parathyroid hormone (PTH) and bone-derived fibroblast growth factor 23 (FGF23).1–3 Disruption of either pathway has been associated with a number of disorders resulting in hypo- or hyperphosphatemia.1 These disorders tend to have profound effects on the human body through demineralization or ectopic calcifications/stone production.1

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Phosphate homeostasis is a complex process involving communication among bones, kidneys, and other organ systems.1,2 This is tightly regulated through parathyroid hormone (PTH) and bone-derived fibroblast growth factor 23 (FGF23).1–3 Disruption of either pathway has been associated with a number of disorders resulting in hypo- or hyperphosphatemia.1 These disorders tend to have profound effects on the human body through demineralization or ectopic calcifications/stone production.1

Key concepts: Hyperphosphatemia, Fibroblast growth factor 23, Medicine, Fibroblast growth factor, Parathyroid hormone, Internal medicine, Endocrinology, Homeostasis

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway — Research Paper | ScholarLens